The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach
No Thumbnail Available
Identifiers
Date
2021-11-01
Authors
Rios-Tamayo, Rafael
Puig, Noemi
Algarin, Macarena
Garcia de Veas Silva, Jose Luis
Barbosa, Nuno
Encinas, Cristina
Hernandez, Jose angel
Alonso, Rafael
Campos, Maria Luisa
Rodriguez, Teresa
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Mdpi
Metrics
Export
Abstract
Despite tremendous progress being made in recent years, multiple myeloma (MM) remains a challenging disease. The laboratory plays a critical role in the overall management of patients. The diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the clinical care process. Conventional laboratory methods have been and continue to be the basis of laboratory testing in monoclonal gammopathies, along with the serum free light chain test. However, more accurate methods are needed to achieve new and more stringent clinical goals. The heavy/light chain assay is a relatively new test which can overcome some of the limitations of the conventional methods for the evaluation of intact immunoglobulin MM patients. Here, we report an update of the evidence accumulated in recent years on this method regarding its use in MM.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
multiple myeloma (MM), heavy, <p>heavy/light chain (HLC) assay</p>, Hevylite(R), diagnosis, prognosis, monitoring, International staging system, Monoclonal gammopathy, Undetermined significance, Residual disease, Uninvolved immunoglobulins, Risk-factor, Follow-up, Long-term, Progression, Survival